Cargando…

The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials

Glucagon-like peptide 1 (GLP-1) based therapy is an established treatment option for the management of type 2 diabetes mellitus (T2DM) and is recommended early in the treatment algorithm owing to glycaemic efficacy, weight reduction and favourable cardiovascular outcomes. Glucose-dependent insulinot...

Descripción completa

Detalles Bibliográficos
Autores principales:	Min, Thinzar, Bain, Stephen C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7843845/ https://www.ncbi.nlm.nih.gov/pubmed/33325008 http://dx.doi.org/10.1007/s13300-020-00981-0

Ejemplares similares

Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
por: Willard, Francis S., et al.
Publicado: (2020)

Effects of Renal Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide
por: Urva, Shweta, et al.
Publicado: (2021)

Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide
por: Urva, Shweta, et al.
Publicado: (2022)

Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis
por: Karagiannis, Thomas, et al.
Publicado: (2022)

Tirzepatide: A Novel, Once-weekly Dual GIP and GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes
por: Kaneko, Shizuka
Publicado: (2022)

Designing a Dual GLP-1R/GIPR Agonist from Tirzepatide: Comparing Residues Between Tirzepatide, GLP-1, and GIP
por: Wang, Lijing
Publicado: (2022)

Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes
por: Hartman, Mark L., et al.
Publicado: (2020)

Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes
por: Thomas, Melissa K, et al.
Publicado: (2020)

Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity
por: Gallwitz, Baptist
Publicado: (2022)

Efficacy and safety of novel twincretin tirzepatide a dual GIP and GLP-1 receptor agonist in the management of type-2 diabetes: A Cochrane meta-analysis
por: Dutta, Deep, et al.
Publicado: (2021)

Efficacy and safety of tirzepatide, dual GLP-1/GIP receptor agonists, in the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials
por: Zhou, Qian, et al.
Publicado: (2023)

A systematic review of the safety of tirzepatide-a new dual GLP1 and GIP agonist - is its safety profile acceptable?
por: Meng, Zhuqing, et al.
Publicado: (2023)

FRI078 Real-World Weight Loss Outcomes And Safety Of Tirzepatide, A Novel Dual GIP And GLP-1 Receptor Agonist
por: Fansa, Sima, et al.
Publicado: (2023)

Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction
por: Nauck, Michael A., et al.
Publicado: (2022)

Research Progress on the GIP/GLP-1 Receptor Coagonist Tirzepatide, a Rising Star in Type 2 Diabetes
por: Ma, Zijun, et al.
Publicado: (2023)

The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect
por: Fisman, Enrique Z., et al.
Publicado: (2021)

Structural insights into multiplexed pharmacological actions of tirzepatide and peptide 20 at the GIP, GLP-1 or glucagon receptors
por: Zhao, Fenghui, et al.
Publicado: (2022)

The Emerging Role of Dual GLP-1 and GIP Receptor Agonists in Glycemic Management and Cardiovascular Risk Reduction
por: Rizvi, Ali A, et al.
Publicado: (2022)

Special Report: Potential Strategies for Addressing GLP-1 and Dual GLP-1/GIP Receptor Agonist Shortages
por: Whitley, Heather P., et al.
Publicado: (2023)

Achieving Normoglycemia With Tirzepatide: Analysis of SURPASS 1–4 Trials
por: Rosenstock, Julio, et al.
Publicado: (2023)

Generalizability of the SURPASS‐2 Trial and Effect of Tirzepatide on US Diabetes and Obesity Control
por: Chiu, Nicholas, et al.
Publicado: (2022)

Patient-Reported Outcomes in People with Type 2 Diabetes Receiving Tirzepatide in the SURPASS Clinical Trial Programme
por: Boye, Kristina S., et al.
Publicado: (2023)

A Dual GLP-1/GIP Receptor Agonist Does Not Antagonize Glucagon at Its Receptor but May Act as a Biased Agonist at the GLP-1 Receptor
por: Al-Zamel, Noura, et al.
Publicado: (2019)

Dual GIP–GLP1-Receptor Agonists In The Treatment Of Type 2 Diabetes: A Short Review On Emerging Data And Therapeutic Potential
por: Bastin, Marie, et al.
Publicado: (2019)

Spatiotemporal GLP-1 and GIP receptor signaling and trafficking/recycling dynamics induced by selected receptor mono- and dual-agonists
por: Novikoff, Aaron, et al.
Publicado: (2021)

Tirzepatide as Monotherapy Improved Markers of Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes (SURPASS-1)
por: Lee, Clare J, et al.
Publicado: (2023)

Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program
por: Lingvay, Ildiko, et al.
Publicado: (2023)

The Upcoming Weekly Tides (Semaglutide vs. Tirzepatide) against Obesity: STEP or SURPASS?
por: Jung, Han Na, et al.
Publicado: (2022)

What combines best with GLP-1 for obesity treatment: GIP receptor agonists or antagonists?
por: Holst, Jens Juul
Publicado: (2021)

Time to Reach Glycaemic and Body Weight Loss Thresholds with Tirzepatide in Patients with Type 2 Diabetes: A Pre-planned Exploratory Analysis of SURPASS-2 and SURPASS-3
por: Viljoen, Adie, et al.
Publicado: (2023)

LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept
por: Coskun, Tamer, et al.
Publicado: (2018)

GIP Receptor Agonism Attenuates GLP-1 Receptor Agonist–Induced Nausea and Emesis in Preclinical Models
por: Borner, Tito, et al.
Publicado: (2021)

The Effects of Dual GLP-1/GIP Receptor Agonism on Glucagon Secretion—A Review
por: Mathiesen, David S., et al.
Publicado: (2019)

The novel dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 (GLP‐1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long‐acting GLP‐1 receptor agonists
por: Urva, Shweta, et al.
Publicado: (2020)

A Dual GLP-1/GIP Receptor Agonist Is More Effective than Liraglutide in the A53T Mouse Model of Parkinson's Disease
por: Zhang, Zijuan, et al.
Publicado: (2023)

The novel GLP-1/GIP dual agonist DA3-CH improves rat type 2 diabetes through activating AMPK/ACC signaling pathway
por: Xu, Jing, et al.
Publicado: (2023)

Dual GIPR and GLP-1R agonist tirzepatide inhibits aeroallergen-induced allergic airway inflammation in mouse model of obese asthma
por: Toki, Shinji, et al.
Publicado: (2023)

Treatment Satisfaction and Quality of Life with Tirzepatide Versus Dulaglutide Among Japanese Patients with Type 2 Diabetes: Exploratory Evaluation of the SURPASS J-mono Trial
por: Ishii, Hitoshi, et al.
Publicado: (2023)

The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Renal Outcomes in Type 2 Diabetes
por: Yin, Win L., et al.
Publicado: (2020)

Species‐specific action of (Pro3)GIP – a full agonist at human GIP receptors, but a partial agonist and competitive antagonist at rat and mouse GIP receptors
por: Sparre‐Ulrich, A H, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_0fmc5d8kq2cmghi6hkufgev4au